The endocrine hormone fibroblast growth factor 21 (FGF21) is induced in the adaptive response to nutrient deprivation, where it serves to regulate the integrated response to fasting via its primary receptor complex, FGF receptor 1 coupled with the cofactor ␤-klotho (KLB) in target tissues. Curiously, endogenous FGF21 levels are also elevated in preclinical models of obesity and in obese/ diabetic individuals. In addition to higher FGF21 levels, reduced KLB expression in liver and adipose tissue has been noted in these same individuals, suggesting that obesity may represent an FGF21 resistant state. To explore the contribution of tissue-specific KLB levels to endogenous FGF21 activity, in both fasting and high-fat diet feeding conditions, we generated animals overexpressing KLB in liver (LKLBOE) or adipose (ATKLBOE). Supportive of tissue-specific partitioning of FGF21 action, after chronic high-fat feeding, ATKLBOE mice gained significantly less weight than WT. Reduced weight gain was associated with elevated caloric expenditure, accompanied by a reduced respiratory exchange ratio and lower plasma free fatty acids levels, suggestive of augmented lipid metabolism. In contrast, LKLBOE had no effect on body weight but did reduce plasma cholesterol. The metabolic response to fasting was enhanced in LKLBOE mice, evidenced by increased ketone production, whereas no changes in this were noted in ATKLBOE mice. Taken together, these data provide further support that specific effects of FGF21 are mediated via engagement of distinct target organs. Furthermore, enhancing KLB expression in adipose may sensitize to endogenous FGF21, thus representing a novel strategy to combat metabolic disease. (Endocrinology 157: 1467-1480, 2016) T he endocrine family of fibroblast growth factors (FGFs) comprising FGF15 (or its human orthologue FGF19), FGF21, and FGF23 has emerged as novel metabolic regulators of bile acid homeostasis, glucose/lipid metabolism, and the phosphate/vitamin D axis, respectively (1, 2). FGF21 is released by the liver and serves to regulate the systemic response to energy restriction (3). The metabolic actions of FGF21 are dependent upon engagement of its tyrosine kinase FGF receptor (primarily FGF receptor 1c) in complex with its coreceptor, ␤-klotho (KLB) in target organs (4 -6). Although KLB is also potentially required for the biological actions of FGF15/19, the role of KLB in the biology of FGF15 in particular is poorly understood due to lack of functional recombinant FGF15 protein or convenient assays to measure its abundance in the blood (7). Because FGF receptor 1 is broadly expressed in multiple tissue types (8), it is the restricted distribution of KLB that defines the target organ selectivity of . In mice, KLB mRNA expression is restricted to the liver, adipose tissue, pancreas and key areas of the central nervous system (CNS) such as the suprachiasmatic nucleus and dorsal vagal complex (11-13). FGF21 itself is expressed in the liver, adipose tissue, skeletal muscle, and the pancreas (14, 15). Muscle (16) and
brown adipose tissue (BAT) (17) can release FGF21 in response to specific physiological stimuli such as cold exposure; however, recent studies have demonstrated that plasma levels are primarily accounted for by the liver (18) .
The hepatic production of FGF21 is associated with physiological/pathophysiological conditions characterized by hepatic stress, including starvation and obesity (19, 20) . The primary physiological action of FGF21 is thought to occur during the adaptive response to nutrient deprivation, where it functions to coordinate the systemic response to caloric deficit (18, 21, 22) . In the physiological context, once released by the liver, FGF21 functions as an autocrine/paracrine factor to regulate hepatic fatty acid metabolism (21, 23) , in an endocrine manner targeting adipose tissue to control plasma free fatty acids (FFA) availability (23) as well as the brain in order to regulate hepatic glucose production, locomotor activity, and reproduction (12, 13, 24) . Production of FGF21 by the liver and its subsequent release are also elevated in response to metabolic dysfunction, where FGF21 is hypothesized to play a protective role (25) . Supportive of this hypothesis, it has recently been reported that FGF21 produced by the liver during the first few weeks of diet-induced obesity serves to aid in maintenance of systemic glucose homeostasis (18) . However, after prolonged exposure to a highfat diet (HFD), downstream signaling is diminished, leading to impairment of its beneficial effects on glycemia (26) .
Taken together, these observations have led to the suggestion that obesity/diabetes may represent a state of FGF21 resistance (15, 26) , although this has been disputed (27) . Therefore, to define the contribution of tissue-specific KLB levels to endogenous FGF21 activity, we generated animals overexpressing KLB in liver (LKLBOE) or adipose tissue (ATKLBOE). Using these models we were able to highlight the tissue-specific activity of endogenous FGF21 in the context of nutrient deprivation and HFD feeding. Our results are supportive of tissue-specific partitioning of FGF21 in response to physiological stress, where it functions as an autocrine/paracrine factor in response to nutrient deprivation in order to aid in the regulation of hepatic ketogenesis and as an endocrine factor acting on adipose tissue to increase caloric expenditure, providing protection from diet-induced obesity.
Materials and Methods

Animals
Male wild-type (WT), LKLBOE, and ATKLBOE mice were individually housed in a temperature-controlled facility with a 12-hour light, 12-hour dark cycle. Animal protocols were approved by the Eli Lilly and Co Institutional Animal Care and Use Committee.
Generation of transgenic mice
Transgenic overexpression of KLB was introduced into the liver and adipose tissue using the mouse albumin and adipocyte protein 2/fatty acid binding protein promoter regions, respectively. Overexpression of KLB was confirmed by PCR using transgene-specific primers and confirmed transgene expression by real-time quantitative PCR and Western blot analysis on RNA and protein isolated from liver, interscapular BAT (iBAT), epididymal white adipose tissue (eWAT), and inguinal WAT (iWAT).
Fasting study
WT (n ϭ 14), LKLBOE (n ϭ 14), and ATKLBOE (n ϭ 14) mice were acclimatized to housing for 7 days before experimentation. Mice were randomly assigned to one of 2 experimental groups where they were exposed to ad libitum (n ϭ 7 for each genotype) access to food or a 24-hour fast (n ϭ 7 for each genotype). Before killing, blood glucose levels were determined. After killing, tissues were rapidly dissected and flash frozen in liquid nitrogen.
HFD study
WT (n ϭ 12), LKLBOE (n ϭ 12), and ATKLBOE (n ϭ 12) mice were fed a high-fat/high-sucrose diet (TD95217; Harlan Teklad) for 12 weeks. Body composition was assessed before and after high-fat feeding using quantitative nuclear magnetic resonance (qNMR). Body weight and food intake were recorded weekly, and at the end of high-fat feeding, mice were housed in metabolic cages (Oxymax Lab Animal Monitoring System; Columbus Instruments) for 24-hours. Body weight and food intake were recorded daily, with body composition assessed again at the end of the experimental period. Before killing, blood glucose levels were determined. After killing, tissues (liver, eWAT, iWAT, and iBAT) were rapidly dissected and flash frozen in liquid nitrogen.
Chronic FGF21 administration
WT (n ϭ 12), LKLBOE (n ϭ 12), and ATKLBOE (n ϭ 12) mice were fed a high-fat/high-sucrose diet (TD95217; Harlan Teklad), for 12 weeks. After this period, animals were weighed and body composition was determined using qNMR. Mice were then randomly assigned to treatment groups in which osmotic minipumps (ALZET) were sc implanted delivering vehicle (PBS; n ϭ 6) or recombinant human FGF21 (n ϭ 6, 0.1 mg/kg⅐d) for 7 days. Body weight and food intake were recorded daily. During the final 24 hours of infusion, mice were placed in metabolic cages (Oxymax Lab Animal Monitoring System; Columbus Instruments). Seven days after the start of the experiment, animals were weighed and body composition was determined using qNMR. Before killing, blood glucose levels were determined. After killing, tissues were rapidly dissected and flash frozen in liquid nitrogen.
Analysis of metabolites and circulating factors
Blood samples were collected on ice before storage of plasma at Ϫ80°C. Triglycerides, cholesterol, and FFA were measured using a Hitachi 912 Clinical Chemistry Analyzer (Roche Diag-nostics). ELISA kits (Millipore and BioVendor, Inc) were used to measure circulating levels of insulin (rat/mouse), adiponectin (mouse kit), and FGF21 (rat/mouse) in plasma samples. All samples for a given hormone were assayed in duplicate within a single assay.
Body composition analysis
Body composition of mice was determined using Quantitative Nuclear Magnetic Resonance analysis (ECHO MRI, 3-1 Composition Analyzer; Echo Medical Systems).
Western blotting
Protein was extracted from samples using cell lysis buffer (radioimmunoprecipitation assay buffer; Thermo Scientific). Membranes were probed both with primary KLB antibody (R&D Systems) and for the housekeeping protein ␤-actin (Abcam). Protein was quantified by densitometry (Quantity One 1-D Analysis Software, version 4.5). Target proteins (KLB) were normalized using housekeeping protein ␤-actin or loading control Ponceau stain (28) .
RNA isolation, RT, and real-time quantitative PCR
RNA was isolated from tissue using TRIzol reagent (Invitrogen) and was reverse transcribed into cDNA using a High-Capacity cDNA Reverse Transcription kit (PE Applied Biosystems). Reactions were performed in triplicate on an ABI Prism 7900HT (PE Applied Biosystems) and were normalized to ␤-actin mRNA (Assays-on-Demand Gene Expression Products; PE Applied Biosystems). Fold changes were calculated as two-delta delta cycle threshold.
Statistical analysis
Data are presented as mean Ϯ SEM. Statistical analysis was performed using a Student's unpaired t test and one-way ANOVA, followed by Dunnett's multiple comparisons test, or a two-way ANOVA, with Bonferroni correction where appropriate. Differences were considered significant when P Ͻ .05.
Results
Baseline characteristic of KLB transgenic mice
To further elucidate the tissue-specific activities of FGF21, we developed mice overexpressing KLB, either in the liver or adipose tissue. In each of the models, overexpression of KLB was confirmed by assessment of both mRNA expression and protein abundance (Figure 1 , A-D). In ATKLBOE mice, KLB mRNA expression was increased by 7-, 16-, and 8-fold in eWAT, iWAT, and iBAT, respectively ( Figure 1A ). This resulted in a significant increase in KLB protein abundance in ATKLBOE mice when compared with WT controls ( Figure 1C ). There was no effect of KLB overexpression on mRNA expression of FGFR1 in adipose tissue and liver of ATKLBOE mice ( Figure 1E ). Although the adipocyte protein 2/fatty acid binding protein 4 promoter is predominantly expressed in adipocytes, it has also been reported to be expressed in other organs/cell types including the CNS and macrophages (29) . Thus, because FGF21 has previously been shown to act in the CNS (12), we measured KLB protein abundance in whole hypothalamus to confirm the tissue specificity of KLB overexpression in the ATKLBOE mice. There was no difference in protein abundance of KLB in whole hypothalamus of ATKLBOE mice when compared with that of control animals (Supplemental Figure 1A) . Furthermore, in WT and ATKLBOE mice, we were unable to detect KLB at the mRNA level in iWAT stromal vascular cells (Supplemental Figure 1B) , the primary site of resident adipose tissue macrophages (30 -32) . In LKLBOE mice, KLB mRNA was increased by 8-fold in the liver ( Figure 1B) , which resulted in a significant increase in hepatic KLB protein abundance ( Figure 1D ). Similar to the ATKLBOE mice, there was no effect of KLB overexpression on the mRNA expression of FGFR1 ( Figure 1F ) in adipose tissue or liver of LKLBOE mice. There was no difference in circulating levels of FGF21 at baseline (Supplemental Figure 1F ); however, we did observe a significant decrease in basal mRNA expression of FGF21 in eWAT and liver of LKLBOE and ATKLBOE mice, (Supplemental Figure 1C ). In contrast, there was no difference in the mRNA expression of FGF15 in the ileum of either KLB-overexpressing model when compared with WT (Supplemental Figure 1D) . Furthermore, at baseline there were no differences in body weight, fat mass, metabolic hormones and circulating metabolites between genotypes (Supplemental Figure 1 , E-N).
LKLBOE mice have an enhanced ketogenic response to fasting
To determine whether overexpression of KLB increases sensitivity to endogenous FGF21 in response to nutrient deprivation, WT, LKLBOE, and ATKLBOE mice were subjected to a 24-hour fast, after which metabolically relevant endpoints were assessed. There was a significant increase in plasma levels of FGF21 in mice from all 3 genotypes at the end of the fast when compared with that of ad libitum-fed mice (Supplemental Figure 1H) . However, induction of plasma FGF21 levels was significantly diminished in LKLBOE mice when compared with that of the ATKLBOE or WT mice (Supplemental Figure 1I ), potentially suggestive of enhanced hepatic FGF21 sensitivity. Characteristic of a state of energy deprivation, there was a significant decrease in plasma glucose (Supplemental Figure 1J ) and insulin (Supplemental Figure 1K) , with no change in circulating adiponectin (Supplemental Figure  1L ) in all genotypes while fasting when compared with the fed state. Furthermore, plasma FFA (Supplemental Figure  1M ) and ␤-hydroxybutyrate concentrations (Supplemen-
press.endocrine.org/journal/endotal Figure 1N ) were significantly increased, indicative of enhanced adipose tissue lipolysis and hepatic ketone body production in mice from all 3 genotypes. However, the induction of ketosis in response to fasting was greater in the LKLBOE cohort (14.8-fold) when compared with WT (9.3-fold) mice, with no difference noted in the ATKLBOE animals when compared with controls (10-fold) (Supplemental Figure 1N ). In eWAT, there was no difference between genotypes in the induction of genes associated with lipid mobilization in response to fasting (Supplemental Figure 2 , A-C). In liver there was a significant increase in the mRNA expres- , fibroblast growth factor receptor 1 (FGFR1) (E and F) mRNA expression in liver, epididymal white adipose tissue (eWAT), inguinal white adipose tissue (iWAT) and interscapular brown adipose tissue (iBAT) in wild-type (WT) (Ⅺ, n ϭ 6), adipose tissue specific KLB overexpressing (ATKLBOE) (f, n ϭ 6), and liver specific KLB overexpressing (LKLBOE) ( , n ϭ 6) mice. Values are group mean Ϯ SEM. Statistical significance is denoted by *, P Ͻ .05 when compared with that of WT sibling control animals. sion of key transcriptional regulators of glucose/fatty acid metabolism and ketone body production, as well as target genes associated with lipid mobilization, cellular and mitochondrial fatty acid delivery, fuel selection, and gluconeogenesis in all mice; however, there were no significant differences between genotypes (Supplemental Figure 2 , D-F).
Adipose KLB overexpression protects mice from diet-induced obesity To determine whether KLB overexpression enhances the sensitivity of liver or adipose tissue to endogenous FGF21, we subjected mice from all 3 genotypes to the chronic stress of HFD-induced obesity. Chronic HFD consumption increased plasma levels of FGF21 in WT and LKLBOE mice to values typical of obese mice (1-3 ng/mL) (26, 27, 33) . However, in the ATKLBOE mice, plasma FGF21 remained within the normal range reported for lean mice, suggestive of enhance endogenous sensitivity to FGF21 (Figure 2, A and B) . In response to high-fat feeding, there was a significant increase in body weight, which was primarily accounted for by significantly increased fat mass in all 3 genotypes (Figure 2, C and D) . However, although Adipose tissue specific ␤-klotho (KLB) overexpression protects mice from diet-induced obesity after 12 weeks of high-fat feeding. Plasma levels of fibroblast growth factor 21 (FGF21) in wild-type (WT) (Ⅺ, n ϭ 12), ATKLBOE (f, n ϭ 12), and liver specific KLB overexpression (LKLBOE) (f, n ϭ 12) mice (A and B) after 12 weeks of diet-induced obesity. Body weight, fat mass change (C and D), and cumulative food intake (E and F) in WT (E), ATKLBOE ( ), and LKLBOE (OE) throughout 12 weeks of high-fat feeding. Values are group mean Ϯ SEM. Statistical significance is denoted by *, P Ͻ .05 when compared with WT.
doi: 10.1210/en.2015-1722 press.endocrine.org/journal/endostill evident, body weight and fat mass gain were significantly attenuated in the ATKLBOE cohort ( Figure 2C ). There was no difference in daily food intake throughout 12 weeks of high-fat feeding between groups (Figure 2, E and F).
KLB-mediated protection from diet-induced obesity is associated with an increased energy expenditure in ATKLBOE mice When corrected for body weight there was a significant increase in caloric expenditure in ATKLBOE mice when compared with that of WT animals maintained on a HFD ( Figure 3A) . However, when uncorrected for weight, although still trending numerically higher, the difference was no longer significant (Supplemental Figure 3A) , thus we are unable presently to conclude that the effect of KLB overexpression is weight independent. Conversely, caloric expenditure trended lower in LKLBOE mice when compared with that WT controls when corrected for body weight ( Figure 3B ) and uncorrected for body weight (Supplemental Figure 3B ). Accompanying the elevation in caloric expenditure there was a significant decrease in respiratory exchange ratio (RER) in ATKLBOE mice when compared with that of WT ( Figure 3C ), indicative of an increased reliance of lipids as an energy source. There was no difference in RER between WT and LKLBOE mice ( Figure 3D ). There were no differences in locomotor activity ( Figure 3 , E and F), glycemic control, or adiponectin levels between any of the genotypes (Figure 4, A-F) . However, there was a differential response to the effect of highfat feeding on plasma lipids between KLBOE mice when compared with that of WT (Figure 4 , G-L). Specifically, ATKLBOE mice exhibited significantly lower plasma FFA levels when compared with the WT mice ( Figure 4H) . Interestingly, we observed significantly lower circulating levels of cholesterol ( Figure 4J ) in LKLBOE mice in response to high-fat feeding when compared with WT. There were no significant differences in FFA levels between the LKLBOE mice and controls ( Figure 4K) ; however, there was significant variance in FFA levels in the plasma of the LKLBOE animals.
Increased caloric expenditure in ATKLBOE mice is associated with the induction of thermogenic gene expression in BAT Next, we investigated the molecular mechanism underlying the attenuated weight gain and improved plasma lipid profile in ATKLBOE mice. In iBAT there was a significant increase in the mRNA expression of the key transcriptional regulator of fatty acid metabolism (peroxisome proliferatoractivated receptor gamma coactivator 1-alpha) and its downstream target genes associated with substrate delivery (glucose transporter-4) and metabolic inefficiency (type II iodothyronine deiodinase and uncoupling protein 1 [UCP1]) in ATKLBOE when compared with WT mice ( Figure 5A ). In contrast, there were no significant differences in metabolic gene expression between LKLBOE mice and WT in adipose tissue or liver at the end of the 12-week high-fat feeding protocol ( Figure 5, B, D, F, and H) .
Given that KLB overexpression appeared to sensitize mice to endogenous FGF21, we went on to examine the effect of KLB overexpression on the sensitivity of obese mice to chronic low-dose (0.1 mg/kg⅐d) recombinant human FGF21 administration. Chronic FGF21 treatment lowered body weight; however, this effect occurred at a similar magnitude in all genotypes ( Figure 6 , A-C). There was no significant effect of FGF21 treatment on food intake in any genotype (Figure 6, D-F) . Given the low dose of FGF21, we were also unable to detect any changes in fed glucose levels at the end of the 7-day treatment period (Figure 6 , G-I). However, there was a significant decrease in plasma insulin levels in all cohorts in response to FGF21 ( Figure 6 , G-I). In WT and ATKLBOE mice, there was a significant decrease in plasma triglyceride levels ( Figure 6 , J and K). This effect was absent in LKLBOE mice treated with FGF21 when compared with vehicle ( Figure 6L ). Plasma cholesterol levels were decreased in WT and AT-KLBOE mice treated with FGF21 ( Figure 6 , J and K). There was no effect of FGF21 treatment on cholesterol levels in LKLBOE mice; however, this may be due to lower basal circulating cholesterol in this group ( Figure 6L ). There was a significant decrease in plasma FFA levels in ATKLBOE mice when compared with vehicle ( Figure 6K ). In contrast, despite elevated circulating levels of FFA in LKLBOE mice there was no effect of FGF21 in this model ( Figure 6O ).
ATKLBOE in HFD-fed mice augments the induction of caloric expenditure in response to exogenous FGF21
Caloric expenditure was significantly increased in all animals treated with exogenous FGF21 (Figure 7 , A-C). However, despite an equivalent decrease in body weight, the magnitude of the increase in caloric expenditure was greater in ATKLBOE mice when compared with WT mice treated with FGF21 ( Figure 7, A and B) . There was a significant decrease in RER in WT mice treated with FGF21 ( Figure 7D ). This effect was absent in ATKLBOE mice ( Figure 7E) ; however, this may be due to reduced RER in response to HFD in this strain before treatment. Surprisingly, in LKLBOE mice, FGF21 induced a significant increase in RER when compared with vehicle, indicative of increased carbohydrate utilization ( Figure 7F) . Consistent with earlier studies, there was no effect of FGF21 treatment on locomotor activity in any of the cohorts (Figure 7, G-I) . 
KLB overexpression enhances the induction of thermogenic genes in iWAT of ATKLBOE mice in response to exogenous FGF21
At the mRNA transcript level, FGF21 treatment was associated with a robust induction of metabolic genes in iWAT and iBAT. In iBAT there was a significant increase in the mRNA expression of genes associated with enhanced thermogenic capacity in WT and ATKLBOE mice treated with FGF21 when compared with vehicle ( Figure  8A) ; however, this effect was absent or attenuated in LKL-BOE mice ( Figure 8A ). In iWAT, there was a significant increase in the mRNA expression of the primary browning marker gene UCP1 in mice from all 3 genotypes treated with FGF21 ( Figure 8B) . However, the induction of browning genes was greater in ATKLBOE mice when compared with that of WT mice treated with FGF21 (Figure 8B ). In liver, there was a significant increase in the mRNA expression of the leptin receptor and decrease in the mRNA expression of stearoyl-Co-enzyme A desaturase-1 of LKLBOE mice treated with FGF21 when compared with that of vehicle ( Figure 8C ). These effects were absent in WT and ATKLBOE mice treated with FGF21 when compared with vehicle ( Figure 8C ).
Discussion
The primary aim of the current study was to highlight the tissue-specific activity of endogenous FGF21 in the context of nutrient deprivation and HFD feeding. FGF21 is a potent metabolic factor, which when administered to obese and diabetic rodent's lowers body weight, normalizes plasma lipid profiles, improves insulin sensitivity, and ameliorates hepatic steatosis (34, 35) . These therapeutic effects are primarily associated with action in liver, WAT. and BAT (36 -41) . In vivo, FGF21 signaling requires the expression and functional activity of its receptor complex (FGFR1c and KLB) in target cells, such that in their absence-specific facets of its therapeutic efficacy are impaired (9, 10, 39) . Here, we developed a mouse model in which the coreceptor KLB was overexpressed in liver or adipose tissue with the aim of sensitizing mice to endogenous FGF21, in order to highlight its tissue-specific effects.
Consistent with the role proposed for FGF21 in prolonged fasting (2, 42), we observed a significant increase in plasma levels of FGF21 in response to a 24-hour fast in WT and KLB-overexpressing mice. However, plasma levels of FGF21 were significantly lower in LKLBOE mice when compared with that of WT, suggesting potentially enhanced sensitivity to endogenous FGF21. Supportive of this hypothesis, plasma levels of ␤-hydroxybutyrate, a marker of FGF21 in vivo pharmacological efficacy (43) , were significantly higher in LKLBOE mice when compared with WT and ATKLBOE mice after a 24-hour fast. Furthermore, despite lower circulating levels of FGF21 in LKLBOE mice, plasma glucose and insulin levels were E and F) and the liver (G and H) in WT (n ϭ 6), ATKLBOE, n ϭ 6), and liver specific ␤-klotho (KLB) overexpression (n ϭ 6) mice. Values are group mean Ϯ SEM. Statistical significance is denoted by *, P Ͻ .05 when compared with WT.
doi: 10.1210/en.2015-1722 press.endocrine.org/journal/endocomparable between genotypes. Taken as a whole, these data not only support the role of FGF21 as a key fasting hormone but go on to suggest that it is primarily due to autocrine/ paracrine action on the liver that it exerts its ketogenic effects.
This leads us to conclude that the increase in plasma FGF21 during fasting may not be the result of intended endocrine action, but instead may be spillover from a specific increase in local concentrations in the liver. Although our fasting studies uncovered a vital role for hepatic KLB and local FGF21, we hypothesized that chronic high-fat feeding may uncover an endocrine role for FGF21 in the adipocyte. Obesity is associated with development of several metabolic and hormonal abnormalities including metabolic inflexibility (44) , in addition to acquired hormonal resistance to both leptin (45) and insulin (46) . Similar to leptin and insulin resistance, plasma levels of FGF21 are also increased in obesity (26) , whereas KLB expression is decreased (47), leading to impairment of FGF21 signaling in both liver and adipose tissue (26) . Taken together, these data have led some researchers to conclude that obesity represents a state of FGF21 resistance (26) .
To determine whether KLB overexpression provides protection from the metabolic abnormalities associated with development of diet-induced obesity, including the reported reduction in KLB mRNA expression (47), we exposed WT and KLBOE mice to the prolonged metabolic stress of highfat feeding. Twelve weeks of high-fat feeding increased plasma FGF21 levels to values reported previously for obese mice in both the WT and LKLBOE cohorts (Ͼ1 ng/mL) (26, 27) . However, in ATKLBOE mice, plasma levels of FGF21 remained within the range typical of lean mice (Ͻ500 pg/ mL), suggesting that augmentation of adipose KLB may be able to enhance endogenous FGF21 sensitivity. In support of this contention, weight gain and fat mass accrual were significantly diminished in ATKLBOE mice when compared with WT mice. In contrast, there was no effect of hepatic KLB overexpression on weight gain, with LKLBOE mice gaining equivalent weight to that of WT animals, further highlighting the tissue-specific activity of FGF21 with regards to its metabolic effects. The antiobesity effect of FGF21 is generally associated with an elevation in caloric expenditure (48, 49) , an effect that is proposed to be linked to FGF21's action in the adipocyte (36, 37, 50) . Corroborating this, the lowered weight gain in ATKLBOE mice was associated with a significant increase in weight corrected caloric expenditure, which appeared to be fueled by the oxidation of circulating lipids. Molecular analysis indicated that these effects were underpinned by the increased mRNA transcript levels of the thermogenic factor UCP1 in BAT. However, our group and others have recently reported that in the absence of UCP1, FGF21 is still able to lower body weight in obese mice (41, 51) . Specifically, in UCP1 null mice, UCP1-independent thermogenic pathways are able to account for approximately 20% of FGF21's effects on caloric expenditure (41) . Thus, here we report that in addition to the stimulation of UCP1, elevated caloric expenditure in ATKLBOE mice was also associated with the induction several other FGF21 thermogenic genes (peroxisome proliferator-activated receptor gamma coactivator 1-alpha, type II iodothyronine deiodinase, and glucose transporter-4) in iBAT that are indicative of a state of metabolic inefficacy (52, 53) . Similar to body weight, there was no effect of KLB overexpression in the liver on energy expenditure, plasma FFA or triglyceride levels. However, in addition to its antiobesity activity FGF21 also potently lowers plasma cholesterol in obese rodents, primates, and humans (43, 54) . Importantly, available evidence suggests that FGF21's cholesterol lowering efficacy is at least partially associated with action in the liver (54 -56) . Here, we report that plasma cholesterol levels were significantly lower in LKLBOE mice in response to high-fat feeding when compared with that of WT. The cholesterol lowering efficacy of FGF21 has been suggested to be linked to the reduction of genes associated with cholesterol homeostasis in the liver (3-hydroxy-3-methylglutaryl-Coenzyme A) (54) . However, there were no differences in the expression of this key mediator of cholesterol homeostasis between WT and LKLBOE at the end of high-fat feeding. FGF15 (or FGF19) has been shown to suppress the mRNA expression of cholesterol-7-hydroxylase (CYP7A1) (26) a key regulator of bile acid production (57) . Thus, it could be hypothesized that the reduction in circulating cholesterol levels in LKLBOE mice may be associated the differential regulation of key path- ways associated with bile acid production. However, here we found that in the basal state there was no difference in mRNA expression of FGF15 in the ileum between genotypes. Furthermore, we failed to detect any differences between the strains mRNA levels of CYP7A1 or is family member CYP8B, known FGF15 target genes. Thus, the lower circulating levels of cholesterol in LKLBOE mice do not appear to be linked with the differential regulation of these classical pathways associated with cholesterol homeostasis and bile acid production in the liver and therefore further studies are required to elucidate their mechanistic basis.
To our surprise overexpression of KLB in adipose or liver did not result in enhanced sensitivity to pharmacologically administered exogenous FGF21 with respect to its antiobesity efficacy. Consistent with previous reports (48, 49) , lowdose FGF21 administration reduced body weight, associated with increased caloric expenditure in all genotypes. The ability of FGF21 to lower plasma cholesterol levels was absent in LKLBOE mice; however, this may be a result of already lowered baseline levels in this model, possibly due to enhanced liver action of endogenous FGF21. In contrast, enhanced sensitivity to exogenous FGF21 was reflected in ATKLBOE mice via FGF21-mediated lowering of circulating FFA levels, an effect that did not occur in WT or LKLBOE mice and may be associated with the enhanced whole-body lipid oxidation rates in ATKLBOE mice. Despite an apparent elevation of circulating FFA in LKLBOE animals there was no significant effect of chronic FGF21 treatment in this model. This trend may be a result of enhanced hepatic FGF21 action in LKL-BOE mice, reducing the activity of FGF21 at the adipocyte, indirectly indicated via reduced lipid oxidation rates. Taken together, these data further highlight the potential of targeting the FGF21/KLB axis in specific tissue/cell types in order to use specific facets of its therapeutic signature with respect to the treatment of obesity and its associated comorbidities.
Our findings in the context of fasting suggest that local action of FGF21 in the liver likely mediates the increases in ketone production. We go on to show for the first time that enhancing the tissue-specific sensitivity of obese mice to endogenous FGF21 via augmentation of KLB in adipose may be a viable strategy in the treatment of obesity and its associated comorbidities. This is of particular importance as existing therapeutics such as rosiglitazone have been shown to increase KLB mRNA levels both in vitro and in vivo (15, 58, 59) , thus, screening for inducers of adipose KLB would likely represent an attractive approach to augment the activity of adipocyte-specific FGF21 pathway. Secondly, our data provide further support to suggest that FGF21 action in adipose tissue accounts for most its metabolic benefits in the context of diet-induced obesity. However, we provide further evidence to suggest that FGF21's action in the liver may partially account for its cholesterol lowering effect. Critically, one can also extrapolate from our findings that obesity likely does represent an FGF21 resistant state and that this resistance can be corrected by increasing the mRNA expression of KLB in FGF21's target tissues.
